Compare ProShares Ultra Silver ETF (AGQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs TG Therapeutics Inc — how do they compare? ProShares Ultra Silver ETF trades at $66.31, while TG Therapeutics Inc trades at $56.46 (market cap $8.89B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $58.06 |
52-Week Low | $48.15 | $26.39 |
Market Cap | — | $8.89B |
Enterprise Value | — | $9.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
